Effect of neoadjuvant epirubicin and total androgen blockade on complete pathological response in patients with clinical stage T3/T4 prostate cancer

European Journal of Surgical Oncology

Volumn 34, Issue 2, 2008, Pages 216-221

  Francini, G ^a   Paolelli, L ^a   Francini, E ^a   Pascucci, A ^a   Manganelli, A ^a   Salvestrini, F ^a   Petrioli, R ^a  

^a UNIVERSITY OF SIENA   (Italy)

Author keywords

Epirubicin; Hormonal therapy; Neoadjuvant treatment; Prostate cancer

Indexed keywords

BICALUTAMIDE; CARBOPLATIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTRAMUSTINE; ETOPOSIDE; KETOCONAZOLE; LEUPRORELIN; MITOXANTRONE; PACLITAXEL; PROSTATE SPECIFIC ANTIGEN; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE HEART FAILURE; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DIGITAL RECTAL EXAMINATION; FATIGUE; FOLLOW UP; GLEASON SCORE; GYNECOMASTIA; HUMAN; MALE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSTOPERATIVE CARE; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; THROMBOCYTOPENIA; TREATMENT OUTCOME; TUMOR VOLUME; UNSPECIFIED SIDE EFFECT; VOMITING;

AGED; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPIRUBICIN; FOLLOW-UP STUDIES; HUMANS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM STAGING; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY, ADJUVANT; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 38149091850     PISSN: 07487983     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejso.2007.03.016     Document Type: Article

References (24)

1. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110-114
2. Lerner S.E., Blute M.L., and Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer: outcome and contemporary morbidity. J Urol 154 (1995) 1447-1452
3. Babaian R.J., Troncoso P., Bhadkamkar V.A., and Johnston D.A. Analysis of clinicopathologic factors predicting outcome after radical prostatectomy. Cancer 91 (2001) 1414-1422
4. Shannon C., and Smith I. Is there still a role for neoadjuvant therapy in breast cancer?. Crit Rev Oncol Hematol 45 (2003) 77-90
5. Bonney W.W., Schned A.R., and Timberlake D.S. Neoadjuvant androgen ablation for localized prostatic cancer pathology methods, surgical end points and meta-analysis of randomized trials. J Urol 160 (1998) 1754-1760
6. Oh W.K., and Kantoff P.W. Treatment of locally advanced prostate cancer: is chemotherapy the next step?. J Clin Oncol 17 (1999) 3664-3675
7. Francini G., Petrioli R., Manganelli A., et al. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer 67 (1993) 1430-1436
8. Petrioli R., Fiaschi A.I., Pozzessere D., et al. Weekly epirubicin in patients with hormone-resistant prostate cancer. Br J Cancer 87 (2002) 720-725
9. Kolvenbag G.J., and Nash A. Bicalutamide dosages used in the treatment of prostate cancer. Prostate 39 (1999) 47-53
10. Labrie F., Dupont A., Cusan L., et al. Downstaging of localized prostate cancer by neoadjuvant therapy with flutamide and lupron: the first controlled and randomized trial. Clin Invest Med 16 (1993) 499-509
11. Soloway M.S., Sharifi R., Wajsman Z., et al. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. The Lupron Depot Neoadjuvant Prostate Cancer Study Group. J Urol 154 (1995) 424-428
12. Powell I.J., Tangen C.M., Miller G.J., et al. Neoadjuvant therapy before radical prostatectomy for clinical T3/T4 carcinoma of the prostate: 5-year followup, phase II Southwest Oncology Group Study 9109. J Urol 168 (2002) 2016-2019
13. Pettaway C.A., Pisters L.L., Troncoso P., et al. Neoadjuvant chemotherapy and hormonal therapy followed by radical prostatectomy: feasibility and preliminary results. J Clin Oncol 18 (2000) 1050-1057
14. Clark P.E., Peereboom D.M., Dreicer L., Levin H.J., Clark S.B., and Klein E.A. Phase II trial of neoadjuvant estramustine and etoposide plus radical prostatectomy for locally advanced prostate cancer. Urology 57 (2001) 281-285
15. Konety B.R., Eastham J.A., Reuter V.E., et al. Feasibility of radical prostatectomy after neoadjuvant chemohormonal therapy for patients with high risk or locally advanced prostate cancer: results of a phase I/II study. J Urol 171 (2004) 709-713
16. Febbo P.G., Richie J.P., George D.J., et al. Neoadjuvant docetaxel before radical prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res 11 (2005) 5233-5240
17. Garzotto M., Myrthue A., Hugano C.S., and Beer T.M. Neoadjuvant mitoxantrone and docetaxel for high-risk localized prostate cancer. Urol Oncol 24 (2006) 254-259
18. Brausi M., Jones W.G., Fossa S.D., et al. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer 31A (1995) 1622-1626
19. Heidenreich A., Sommer F., Ohlmann C.H., et al. Prospective randomized phase II trial of pegylated doxorubicin in the management of symptomatic hormone-refractory prostate carcinoma. Cancer 101 (2004) 948-956
20. Lee H.M., Solan M.J., Lupinacci P., Gomella L.G., and Valicenti R.K. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy. Urology 64 (2004) 84-89
21. Alumkal J.J., and Carducci M.A. Early use of chemotherapy in conjunction with radical prostatectomy. Clin Prostate Cancer 3 (2004) 144-149
22. Albertsson P., Lennernas B., and Norrby K. On metronomic chemotherapy: modulation of angiogenesis mediated by VEGF-A. Acta Oncol 45 (2006) 144-155
23. Damber J.-E., Vallbo C., Albertsson P., Lennernas P., Lennernas B., and Norrby K. The anti-tumour effect of low-dose continuous chemotherapy may partly be mediated by thrombospondin. Cancer Chemother Pharmacol 58 (2006) 354-360
24. Browder T., Butterfield C.E., Kraling B.M., et al. Antiangiogenic scheduling of chemotherapy improves efficacy against exeprimental drug-resistant cancer. Cancer Res 60 (2000) 1878-1886